GLP-1 drugs before anesthesia
Should GLP-1 receptor agonists be continued or withheld before anesthesia? Compare residual gastric-content studies with actual aspiration outcomes, and distinguish elective surgery from endoscopy.
Published studies
Open in feedRecent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.
Showing 7 of 87 · Meta-analysis
Recent evidence · past year
-
Do Preoperative Glucagon-Like Peptide-1 Receptor Agonists Influence Lumbar Fusion Outcomes? A Systematic Review and Meta-Analysis.
AI summary of the abstract, unverified
- Systematic review and meta-analysis of seven retrospective cohorts (28,525 patients) comparing lumbar fusion patients with and without preoperative GLP-1RA exposure.
- Six of the seven studies used propensity score matching or another matching strategy to balance the comparison groups.
- No significant association with reoperation or revision (OR 0.74, 95% CI 0.44-1.24; P = 0.25) or postoperative infection (OR 0.83, 95% CI 0.68-1.00; P = 0.05).
- The authors found no signal of increased postoperative risk and called for prospective studies with standardized exposure definitions and perioperative management protocols.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in patients with obesity and type 2 diabetes, but lumbar fusion-specific associations with postoperative outcomes remain uncertain. OBJECTIVE: To evaluate the association between preoperative GLP-1RA exposure and surgical and postoperative outcomes in adults undergoing lumbar fusion. METHODS: PubMed, Embase, and the Cochrane Library were searched from inception through 14 May 2026. Comparative studies of adults undergoing lumbar fusion with and without preoperative GLP-1RA exposure were included. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I). Random-effects meta-analyses generated odds ratios with 95% confidence intervals. The protocol was prospectively registered in PROSPERO (CRD420261414637). RESULTS: Seven retrospective cohorts involving 28,525 patients were included; 6 used propensity score matching or another matching strategy. No statistically significant associations were observed between preoperative GLP-1RA exposure and reoperation or revision (OR: 0.74, 95% CI: 0.44-1.24; P = 0.25), postoperative infection (OR: 0.83, 95% CI: 0.68-1.00; P = 0.05), wound complications (OR: 0.86, 95% CI: 0.65-1.12; P = 0.26), or postoperative respiratory complications (OR: 1.08, 95% CI: 0.63-1.84; P = 0.69). Deep vein thrombosis, pulmonary embolism, and unplanned emergency department visits also did not differ significantly. All included studies were observational and predominantly used large administrative data sources. CONCLUSIONS: Across the evaluated outcomes, the available observational evidence did not identify a signal of increased postoperative risk associated with preoperative GLP-1RA exposure after lumbar fusion. Prospective studies with standardized exposure definitions and perioperative management protocols are warranted to confirm these findings and better define their clinical implications. CLINICAL RELEVANCE: Current observational evidence does not establish preoperative GLP-1RA exposure alone as an independent risk factor for adverse outcomes after lumbar fusion.
-
[Efficacy and safety of GLP-1 receptor agonists combined with bariatric surgery for obesity: a timing-stratified systematic review].
AI summary of the abstract, unverified
- Systematic review and random-effects meta-analysis of 27 studies, 13 of them in efficacy meta-analyses, searching PubMed, Web of Science and Embase to June 2026.
- Compared GLP-1 receptor agonist use by timing relative to bariatric surgery: preoperative, early postoperative (around 1 month), later postoperative (around 6 months), and rescue after weight regain or insufficient loss.
- Preoperative use raised preoperative weight loss (pooled SMD 0.52, 95% CI 0.25-0.79), but 12-month total body weight loss was 2.85 points lower (95% CI -4.35 to -1.36). Rescue use added 10.30 points (95% CI 6.40-14.20) across four RCTs.
- Authors conclude that rescue use has the strongest evidence, early postoperative use may add weight loss within the first year, and adverse events are mainly gastrointestinal with serious events uncommon.
Original abstract (PubMed)
Objective: To systematically evaluate the efficacy and safety of GLP-1 receptor agonists applied at different stages before and after bariatric surgery, and to compare the clinical benefits of preoperative use, early postoperative use, and rescue use after insufficient weight loss or weight regain according to medication timing. Methods: PubMed, Web of Science, and Embase via Ovid were searched from inception to June 20, 2026. A relatively strict three-concept search strategy was used, consisting of terms related to bariatric surgery, GLP-1 receptor agonists and specific drug names, and perioperative or weight-management scenarios. Searches were mainly restricted to title and abstract fields, and animal-only studies were excluded. Clinical studies involving patients who underwent metabolic and bariatric surgery and received GLP-1 receptor agonists before or after surgery were included. Studies were classified into three groups according to medication timing: preoperative use, early postoperative use, and rescue use after insufficient weight loss or weight regain. Mean difference or standardized mean difference was used for continuous variables, and odds ratio was used for categorical variables. Meta-analysis was performed using a random-effects model. Results: A total of 27 studies were included in the systematic review, including 10 studies on preoperative use, 4 on early postoperative use, and 13 on rescue use after insufficient weight loss or weight regain. Among them, 13 studies were included in efficacy meta-analyses. Preoperative use of GLP-1 receptor agonists improved preoperative weight loss, with a pooled SMD of 0.52 (95%CI: 0.25-0.79, I²=0%, P<0.05). However, when postoperative weight loss at 12 months was assessed using body weight at surgery as the baseline, the percentage of total body weight loss at 12 months was 2.85 percentage points lower in the preoperative medication group than in the non-medication group (95%CI: -4.35 to -1.36, I²=37.7%, P<0.05). Active addition of GLP-1 receptor agonists around 1 month after surgery increased the percentage of total body weight loss at 6 months by an additional 3.62 percentage points (95%CI: 1.88-5.37, I²=0%, P<0.05). Initiation of GLP-1 receptor agonists around 6 months after surgery resulted in an additional weight loss of 7.48 kg during subsequent follow-up compared with controls (95%CI: 5.35-9.60, I²=34.6%, P<0.05). For rescue therapy, four randomized controlled trials showed that GLP-1 receptor agonists resulted in an additional 10.30 percentage points of endpoint percentage weight loss compared with placebo or usual care (95%CI: 6.40-14.20, I²=89.2%, P<0.05). Regarding safety, among studies that clearly reported event numbers, the pooled incidences of nausea, constipation, diarrhea, and vomiting were 25.3%, 19.0%, 9.2%, and 8.6%, respectively. Serious adverse events were uncommon. Conclusion: GLP-1 receptor agonists have timing-specific value in the comprehensive management of metabolic and bariatric surgery. Preoperative use can increase preoperative weight loss but does not enhance postoperative weight loss when body weight at surgery is used as the baseline. Early postoperative use may further amplify weight-loss benefits within the first postoperative year. Rescue use after insufficient weight loss or weight regain is supported by the strongest evidence. In terms of safety, adverse events are mainly gastrointestinal, and serious adverse events are uncommon.
PubMed 42927970 Publisher (DOI) PubMed types: Systematic Review, Journal Article, Meta-Analysis, English Abstract -
Impact of GLP-1 Agonists on Post-Operative Outcomes in Aesthetic & Body Contouring Surgery: A Systematic Review & Meta-Analysis.
AI summary of the abstract, unverified
- Systematic review and meta-analysis following PRISMA guidelines, including 12 studies with 29,357 patients (10 pooled) in aesthetic and body-contouring surgery.
- Exposure was GLP-1 receptor agonist use compared with patients not taking these drugs, with outcomes including infection, dehiscence, healing, scarring, seroma, hematoma, and VTE.
- Pooled observational analyses linked GLP-1 RA use with higher risks of delayed wound healing and hypertrophic scarring; the abstract reports no effect sizes or CIs.
- A subgroup comparison found lower seroma rates in GLP-1 RA users than in patients with prior bariatric surgery, and the authors call for prospective studies.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have rapidly expanded in use for weight loss, resulting in a growing population of patients presenting for aesthetic and body-contouring procedures. Despite their increasing prevalence, the effects of GLP-1 RAs on postoperative wound healing and surgical outcomes remain poorly defined. METHODS: A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. PubMed, Embase, and Cochrane CENTRAL were searched from database inception through May 2026. Studies comparing postoperative outcomes in patients undergoing aesthetic and/or body-contouring surgery with and without GLP-1 RA exposure were included. Primary outcomes included infection, wound dehiscence, delayed wound healing, hypertrophic scarring, seroma, hematoma, and venous thromboembolism (VTE). Random-effects meta-analyses were performed using risk ratios (RRs) with 95% confidence intervals (CIs). RESULTS: Twelve studies comprising 29,357 patients met inclusion criteria, with 10 studies included in quantitative synthesis. In pooled observational analyses, GLP-1 RA exposure was associated with increased risk of delayed wound healing and hypertrophic scarring. Subgroup analysis comparing GLP-1 RA users with patients who had previously undergone bariatric surgery demonstrated decreased seroma rates in the GLP-1 RA group. CONCLUSIONS: GLP-1 RA use in patients undergoing aesthetic and body-contouring surgery was associated in pooled observational analyses with increased risks of delayed wound healing and hypertrophic scarring, while GLP-1 RA use was associated with lower seroma rates in comparison with patients who have undergone bariatric surgery. As GLP-1 RA use become increasingly prevalent, further prospective studies are needed to clarify their perioperative effects and optimize patient selection and surgical outcomes.
-
GLP-1 Receptor Agonists and Insulin Versus Insulin for Perioperative Glycemic Control in Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Systematic Review.
AI summary of the abstract, unverified
- Systematic review of three randomized controlled trials including 168 adults with type 2 diabetes undergoing cardiac surgery.
- Compared liraglutide added to insulin with insulin alone or placebo, assessing perioperative glucose, variability, insulin adjustments, and hypoglycemia.
- Liraglutide was associated with lower glucose, reduced glycemic variability, and fewer insulin adjustments, with low hypoglycemia, though the abstract reports no effect sizes or p values.
- Nausea and vomiting were more frequent with liraglutide; the authors call the evidence preliminary and call for larger, standardized trials with long-term outcomes.
Original abstract (PubMed)
Perioperative hyperglycemia is common in patients with type 2 diabetes undergoing cardiac surgery and is linked to adverse outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer glucose-dependent insulinotropic effects and potential cardiac benefits, but their perioperative role remains uncertain. This review evaluated the efficacy and safety of GLP-1 RA therapy as an adjunct to insulin in this setting. Three electronic databases (PubMed, Cochrane, and Google Scholar) were searched for relevant articles up to October 2025. The primary endpoint was blood glucose levels during the perioperative period, while secondary endpoints included hypoglycemia incidence, total insulin requirement, time in target glucose range, and postoperative complications. Three randomized controlled trials (RCTs) including 168 patients with type 2 diabetes undergoing cardiac surgery were assessed. Perioperative use of liraglutide (subcutaneously in doses of 0.6-1.8 mg/day) was associated with preliminary evidence of improved glycemic control across preoperative, intraoperative, and early postoperative periods, including lower glucose levels, reduced glycemic variability, and fewer insulin adjustments, with a low incidence of hypoglycemia. However, heterogeneity in dosing, timing, and monitoring protocols across studies limits direct comparisons. Mild gastrointestinal adverse events, such as nausea and vomiting, were more frequent with liraglutide. One study reported exploratory immunometabolic effects in adipose tissue. Preliminary evidence from these heterogeneous studies suggests that adding liraglutide to insulin may improve perioperative glycemic control compared to insulin or placebo in patients with type 2 diabetes undergoing cardiac surgery. However, findings are limited by the small number of studies, methodological variability, and lack of long-term outcomes, necessitating larger, standardized trials.
-
Safety and Glycemic Efficacy of Perioperative Liraglutide in Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
AI summary of the abstract, unverified
- Systematic review and meta-analysis of 4 RCTs (7 reports, 446 randomized adults) comparing perioperative subcutaneous liraglutide with placebo or insulin-based usual care in cardiac surgery.
- Liraglutide was compared with placebo or insulin usual care, with glycemic efficacy and hypoglycemia risk as the central questions.
- Liraglutide did not change 30-day mortality (1/161 vs 3/160; RR 0.42, 95% CI 0.06-2.81) or the composite postoperative complication outcome (RR 0.92, 95% CI 0.74-1.14).
- Hypoglycemia was similar (8/165 vs 9/166; RR 0.85, 95% CI 0.34-2.13), and nausea/vomiting estimates were very imprecise (RR 3.01, 95% CI 0.26-35.27).
Original abstract (PubMed)
Perioperative hyperglycemia in cardiac surgery is associated with wound infection, acute kidney injury, and death, yet the intravenous insulin used to treat it is itself coupled to hypoglycemia. Glucagon-like peptide-1 receptor agonists lower glucose only when glucose is elevated and might therefore separate glycemic control from hypoglycemic risk. We searched PubMed/MEDLINE, Scopus, Web of Science, and CENTRAL through September 2025 for randomized controlled trials of perioperative subcutaneous liraglutide versus placebo or insulin-based usual care in adults undergoing cardiac surgery. Two reviewers screened, extracted data, and applied the Cochrane Risk of Bias 2 tool independently; certainty was graded using GRADE. Effects were pooled by inverse variance, fixed-effect when I2 was below 50%. Seven reports of 4 trials, enrolling 446 randomized patients, were eligible. Liraglutide did not alter 30-day mortality (1/161 vs 3/160; risk ratio [RR] 0.42, 95% confidence interval [CI], 0.06-2.81), the composite of any postoperative complication (68/129 vs 76/132; RR 0.92; 95% CI, 0.74-1.14), cardiac adverse events (RR 1.08; 95% CI, 0.83-1.40), hypoglycemia (8/165 vs 9/166; RR 0.85; 95% CI, 0.34-2.13), or postoperative nausea and vomiting (RR 3.01; 95% CI, 0.26-35.27).
-
Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes.
AI summary of the abstract, unverified
- This systematic review pooled 12 case reports describing 13 adults who developed gastroparesis while taking a GLP-1 receptor agonist.
- Semaglutide was the agent most often implicated, followed by liraglutide, dulaglutide, and exenatide, with symptoms often following dose escalation or inappropriate re-initiation.
- Stopping the causative GLP-1 receptor agonist resolved symptoms in all reported patients, though the review reports no effect sizes or confidence intervals.
- The authors call for awareness of this association and recommend careful patient selection, gradual dose titration, and monitoring for persistent GI symptoms.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the treatment of type 2 diabetes mellitus and obesity. Although gastrointestinal adverse effects are common, gastroparesis is an under-recognised but clinically important complication. This systematic review summarises published evidence on the presentation, diagnosis, management, and outcomes of gastroparesis associated with GLP-1RA therapy in real-world clinical practice. METHODS: A systematic review was conducted in accordance with PRISMA 2020 guidelines. PubMed, Embase, Scopus, and Web of Science were searched from inception to October 2025 for reports of symptomatic gastroparesis associated with GLP-1RA use. Eligible studies included case reports, case series, observational studies, and clinical trials involving adults treated with GLP-1RAs for diabetes or weight loss. Data extraction focused on patient characteristics, GLP-1RA exposure, clinical presentation, diagnostic findings, management strategies, and outcomes. Methodological quality was assessed using the Joanna Briggs Institute checklist for case reports. RESULTS: Twelve case reports describing 13 patients met inclusion criteria. Most patients were female and had type 2 diabetes mellitus, though cases also occurred in non-diabetic individuals. Semaglutide was the most frequently implicated agent, followed by liraglutide, dulaglutide, and exenatide. Symptom onset ranged from hours to several months after treatment initiation, commonly following dose escalation or inappropriate re-initiation. Presentations varied from acute to chronic. Reported symptoms included nausea, vomiting, abdominal pain, bloating, early satiety, and oral intolerance. Diagnostic evaluation often demonstrated gastric distension or retained gastric contents on imaging or endoscopy in the absence of mechanical obstruction. Gastric emptying scintigraphy confirms delayed emptying in selected cases. Management primarily involved supportive and symptomatic care. Discontinuation of the offending GLP-1RA led to symptom resolution in all reported patients. CONCLUSION: GLP-1 receptor agonists may induce or worsen gastroparesis in both diabetic and non-diabetic patients, particularly following rapid dose escalation or inappropriate dosing. Awareness of this association is essential for timely diagnosis and management. Withdrawal of the causative agent is central to treatment and is associated with favourable outcomes and reversibility of gastric dysfunction. Careful patient selection, gradual dose titration, and monitoring for persistent gastrointestinal symptoms are recommended to optimise the safe use of GLP-1RAs.
-
Impact of glucagon-like peptide-1 receptor agonists on outcomes following anterior cervical discectomy and fusion: a systematic review and meta-analysis.
AI summary of the abstract, unverified
- Systematic review and meta-analysis of eight retrospective cohort studies, covering 311,402 ACDF patients including 8,182 GLP-1RA users matched to non-users.
- Compared perioperative GLP-1RA use with non-use for pseudarthrosis, reoperation, dysphagia, deep vein thrombosis, and readmission after ACDF.
- Lower pseudarthrosis odds at 6 months (OR 0.60, 95% CI 0.52 to 0.71), 12 months (OR 0.62, 0.53 to 0.73), and 24 months (OR 0.67, 0.57 to 0.79).
- Findings for reoperation, dysphagia, deep vein thrombosis, and readmission were heterogeneous and inconsistent, so evidence on other complications is inconclusive.
Original abstract (PubMed)
OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for type 2 diabetes mellitus and obesity. Their metabolic, anti-inflammatory, and osteogenic effects raise important questions regarding their influence on spinal fusion. To date, no systematic review has specifically investigated how GLP-1RAs influence outcomes following the common anterior cervical discectomy and fusion (ACDF). This study aimed to evaluate the association between perioperative GLP-1RA use and outcomes following ACDF. METHODS: Following PRISMA guidelines, MEDLINE, Embase, PubMed, and the Cochrane Library were searched from inception to February 2026 for studies evaluating GLP-1RA exposure in the context of ACDF. Eligible studies included human observational cohort studies. Data were extracted independently by two reviewers. RESULTS: Eight retrospective cohort studies analysing 311,402 ACDF patients were included, of whom 8,182 were GLP-1RA users matched to non-users. Random-effects meta-analysis demonstrated significantly lower odds of pseudarthrosis among GLP-1RA users at 6 months (OR = 0.60, 95% CI: 0.52 to 0.71; I² = 16.6%), 12 months (OR = 0.62, 95% CI: 0.53 to 0.73; I² = 39.1%), and 24 months (OR = 0.67, 95% CI: 0.57 to 0.79; I² = 34.9%). Findings for reoperation, dysphagia, deep vein thrombosis, and readmission were heterogeneous and inconsistent across studies. CONCLUSION: Perioperative GLP-1RA use was associated with lower odds of pseudarthrosis. However, evidence regarding other postoperative complications remains inconclusive. Future prospective studies are required to further elucidate the impact of GLP-1RA use on ACDF outcomes. LEVEL OF EVIDENCE: Level III, therapeutic study.
Earlier evidence / dates not confirmed
Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.
- No matching papers in this section with the selected filters.
Ongoing registrations
From ClinicalTrials.govRegistrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.
No registered ongoing trials found.